Diffusion Pharmaceuticals (DFFN) Financials

$9.25

$0.58 (6.69%)

As on 18-Oct-2023 09:30EDT

Market cap

$9 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	13.73	15.97	16.04	15.97	11.55	12.03
Operating Profit (EBIT)	-31.33	-15.97	-24.68	-15.97	-11.55	-18.96
Other Income	--	--	--	--	--	--
Profit before Tax	-13.08	-15.59	-24.54	-15.86	-11.47	-18.81
Provision for Tax	8,358.16	-0.38	-0.44	-1.68	0.33	-0.44
Profit after Tax (Net Income)	-8,371.24	-15.21	-24.10	-14.19	-11.80	-18.37
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-2.80	--	-24.10	-16.14	-11.80	-26.62

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	14.23	20.22	34.91	24.81	20.13	15.61
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	532.55	1.29	0.95	0.48	2.25	1.79
Current Liabilities	1.46	2.42	2.93	2.44	1.72	0.80
Total Liabilities	17.16	22.64	37.84	27.73	24.11	18.20

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	--	--	0.02	8.95	9.46	9.29
Current Assets	15.69	22.64	37.82	18.78	14.65	8.91
Total Assets	17.16	22.64	37.84	27.73	24.11	18.20
Total Debt*	--	--	--	0.15	0.25	--
Net Current Assets	14.23	20.22	34.90	16.34	12.93	8.11

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-14.97	-14.50	-13.55	-9.86	-10.77
Cash Flow from Investing Activities	--	--	0.00	0.00	0.00	0.00
Cash from Financing Activities	--	0.01	33.30	17.89	16.04	9.87
Net Cash Inflow / Outflow	--	--	--	4.34	6.19	-0.91

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-4,104.15	-7.46	-11.82	-11.08	-17.10	-272.15
Cash EPS ($)	--	-7.46	-11.78	-11.00	-16.95	-270.51
Adjusted Book Value ($)	--	9.92	17.13	19.38	29.17	231.28
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-7.34	-7.12	-10.59	-14.28	-159.60
Free Cash Flow per Share ($)	--	-7.34	-7.12	-10.59	-14.28	-159.60

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-55.18	-80.49	-62.57	-65.57	-98.26
ROE (%)	-48,603.09	-55.18	-80.69	-63.12	-66.02	-99.72
ROA (%)	-34,267.18	-50.30	-73.50	-54.73	-55.77	-82.84
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-280.77	35.28	-54.47	-38.29	-126.50	64.13
Net Profit Growth (%)	-34,456.77	36.87	-69.86	-20.22	35.77	-1,246.25
EPS Growth (%)	-34,431.15	0.37	-0.07	0.35	0.94	-8.61
Book Value Growth (%)	-46.68	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.68	-0.03	-0.07	-0.03	-0.01
Price / Book Value	0.51	0.51	0.02	0.04	0.02	0.01
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.65	0.77	5.02	1.09	1.19	1.57
Close Price ($)	5.01	7.59	22.88	59.63	34.55	149.25
High Price ($)	13.11	29.69	138.75	120.00	825.00	2,340.00
Low Price ($)	5.01	6.96	21.58	18.75	15.83	137.25
Market Cap ($ Cr)	8.98	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	--	--	0.01	0.01	--
Short term debt to equity ratio	--	--	--	0.00	0.01	--
Current Ratio	10.71	9.36	12.92	7.71	8.51	11.09
Quick Ratio	10.71	--	--	--	--	--
Interest Coverage	1.00	-41.95	-1.44	-139.82	-0.14	-33.63

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.